Asia-Pacific Neuropathic Pain Market, By Type (Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation (Tens) Devices), Product Type (Rechargeable and Non-Rechargeable), Procedure (Invasive and Non-Invasive), Technology (Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation and Respiratory Electrical Stimulation), Modality (Stationary and Portable), Mode of Purchase (Over-the-Counter Devices and Prescription-Based Devices), Pain Type (Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain, Coccydynia), Indication (Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, Others), End User (Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Third Party Distributor and Others) – Industry Trends and Forecast to 2030.
Asia-Pacific Neuropathic Pain Market Analysis and Size
Increasing R&D expenditure by various market players to create advanced products is expected to drive the growth of the Asia-Pacific neuropathic pain market. Limitation associated with medical devices which limits the use of products is expected to act as restraint for the growth of the Asia-Pacific neuropathic pain market. High risk of neuropathic pain with ageing and rising older population in many countries will create an opportunity for the growth of the Asia-Pacific neuropathic pain market. Use of traditional therapies in emerging countries due to low health expenditure and disrupted supply chain is expected to act as a challenge for the growth of the Asia-Pacific neuropathic pain market.
Data Bridge Market Research analyses that the Asia-Pacific neuropathic pain market which was USD 5.45 billion in 2022, is expected to reach USD 10.67 million by 2030, and is expected to undergo a CAGR of 9.8% during the forecast period. This indicates that the market value. “Spinal Cord Stimulation (SCS) Devices” dominates the product segment of the Asia-Pacific neuropathic pain market owing to the growing burden of infectious diseases. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asia-Pacific Neuropathic Pain Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation (Tens) Devices), Product Type (Rechargeable and Non-Rechargeable), Procedure (Invasive and Non-Invasive), Technology (Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation and Respiratory Electrical Stimulation), Modality (Stationary and Portable), Mode of Purchase (Over-the-Counter Devices and Prescription-Based Devices), Pain Type (Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain, Coccydynia), Indication (Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, Others), End User (Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Third Party Distributor and Others)
|
|
Countries Covered
|
Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Siemens (Germany), BD (Becton, Dickinson and Company) (U.S.), Thermo Fisher Scientific (U.S.), QIAGEN (Netherlands), ProImmune Ltd. (U.K.), Creative Biolabs (U.S.), HistoGenetics LLC (U.S.), UCLA Health (U.S.), Quick Biology Inc. (U.S.), TBG Diagnostics Limited (China), Fujirebio (Japan), Medtronic (Ireland), Omixon Inc. (U.S.), Takara Bio Inc. (Japan), Biofortuna Limited (U.K.), Luminex Corporation (U.S.), Hologic, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Revenue cycle management is the management of all administrative and clinical operations that lead to patient service and directly or indirectly to revenue to maximize profits. It allows health providers to increase their income by processing claims. Revenue cycle management includes medical coding, patient registration, payment and accounst receivable management, insurance eligibility and verification, and claim processing.
Asia-Pacific Neuropathic Pain Market Dynamics
Drivers
- Growing Prevalence of Neuropathic Pain
The Asia-Pacific region is witnessing a rise in the prevalence of neuropathic pain, attributed to factors like an aging population, increased incidence of chronic diseases, and lifestyle changes. This surge in patient numbers is a primary driver for the market.
- Advancements in Healthcare Infrastructure
Improvements in healthcare infrastructure, particularly in countries like China and India, are expanding the accessibility of diagnosis and treatment options for neuropathic pain, driving market growth.
- Rising Awareness and Diagnosis
Increasing awareness of neuropathic pain among both healthcare professionals and patients is leading to early diagnosis and intervention, contributing to market expansion.
- Innovative Therapies and Medications
The development of novel therapies, including medications and medical devices, for neuropathic pain management is stimulating market growth. These innovations offer improved pain relief and fewer side effects
Opportunities
- Expanding Geriatric Population
The Asia-Pacific region has a rapidly aging population. As elderly individuals are more susceptible to neuropathic pain, this demographic shift presents a significant opportunity for market growth.
- Technological Advancements
Ongoing research and development efforts are likely to yield more effective and less invasive treatment options, providing opportunities for companies to introduce innovative products and therapies.
Restraints/Challenges
- Limited Access to Healthcare
Despite improvements, healthcare access remains limited in certain remote and underserved areas of the Asia-Pacific region, posing challenges for patients in need of neuropathic pain diagnosis and treatment.
- High Treatment Costs
The cost of advanced treatments for neuropathic pain can be prohibitive for many patients, particularly in countries with limited insurance coverage. This factor could impede market growth.
This Asia-Pacific Neuropathic Pain Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asia-Pacific neuropathic pain market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In December 2021, Boston Scientific Corporation announced that they have launched WaveWriter Alpha Spinal Cord Stimulator Systems. This product is used for chronic pain and can be used in neuropathic pain. This launch will add up to the company's revenue and gain the market share in the forecasted period 2023-2030
Asia-Pacific Neuropathic Pain Market Scope
The Asia-Pacific neuropathic pain market is segmented on the basis of the product type, procedure, technology, modality, mode of purchase, pain type, indication end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Spinal Cord Stimulation (SCS) Devices
- External Peripheral Nerve Stimulation
- Transcutaneous Electrical Nerve Stimulation (Tens) Devices
Product Type
- Rechargeable and Non-Rechargeable
Procedure
- Invasive and Non-Invasive
Technology
- Transcutaneous Electrical Nerve Stimulation
- Transcranial Magnetic Stimulation
- Respiratory Electrical Stimulation
Modality
- Stationary
- Portable
Mode of Purchase
- Over-the-Counter Devices
- Prescription-Based Devices
Pain Type
- Peripheral Neuropathy
- Entrapment Neuropathy
- Phantom Limb Neuropathy
- Trigeminal Neuralgia
- Post Herpetic Neuralgia (PHN)
- Post Traumatic Neuropathy
- Foot Pain
- Coccydynia
Indication
- Spinal Stenosis
- Chemotherapy-Induced Peripheral Neuropathy
- Diabetic Neuropathy
- Others
End User
- Hospitals
- Clinics
- Home Healthcare
- Ambulatory Surgical Centers
- Others
Distribution Channel
- Direct Tender
- Third Party Distributor
- Others
Asia-Pacific Neuropathic Pain Market Regional Analysis/Insights
Asia-Pacific neuropathic pain market is analysed and market size insights and trends are provided by type, product type, procedure, technology, modality, mode of purchase, pain type, indication end user and distribution channel as referenced above.
The countries covered in the Asia-Pacific neuropathic pain market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
China and India will dominate the growth in Asia-Pacific HLA typing transplant diagnostics services market due to increasing population, better healthcare facilities as well as increase in public-private support to develop and research in HLA typing transplantation. These countries have also been seen as medical tourism destination due to the presence of its advanced medical treatments.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The Asia-Pacific neuropathic pain market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Asia-Pacific neuropathic pain market , impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Asia-Pacific neuropathic pain market The data is available for historic period 2015-2020.
Competitive Landscape and Asia-Pacific Neuropathic Pain Market Share Analysis
The Asia-Pacific neuropathic pain market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Asia-Pacific neuropathic pain market .
Some of the major players operating in the Asia-Pacific Neuropathic Pain Market are:
- Johnson & Johnson Private Limited (U.S.)
- Siemens (Germany)
- BD (Becton, Dickinson and Company) – (U.S.)
- Thermo Fisher Scientific (U.S.)
- QIAGEN (Netherlands)
- ProImmune Ltd. (U.K.)
- Creative Biolabs (U.S.
- HistoGenetics LLC (U.S.)
- UCLA Health (U.S.)
- Quick Biology Inc. (U.S.)
- TBG Diagnostics Limited (China)
- Fujirebio (Japan)
- Medtronic (Ireland)
- Omixon Inc. (U.S.)
- Takara Bio Inc. (Japan)
- Biofortuna Limited (U.K.)
- Luminex Corporation (U.S.)
- Hologic, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Bio-Rad Laboratories (U.S.)
SKU-